Roth/MKM Commences Arcturus Therapeutics Coverage with Buy Rating and $20 Price Objective
Roth/MKM has initiated coverage on Arcturus Therapeutics, assigning a Buy rating and setting a price target of $20.00, indicating an anticipated upside of 163% from current trading levels. The biotech has experienced notable share price declines amidst various challenges, but analysts emphasize its strong cash position and promising clinical progra…